UBS Group AG - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 97 filers reported holding Y-MABS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
UBS Group AG ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$106,455
-25.6%
19,533
-7.3%
0.00%
Q2 2023$143,045
-62.6%
21,067
-72.4%
0.00%
Q1 2023$382,078
+109.9%
76,263
+505.6%
0.00%
Q3 2022$182,000
-53.0%
12,594
-50.7%
0.00%
Q2 2022$387,000
-75.7%
25,569
-80.9%
0.00%
-100.0%
Q1 2022$1,594,000
+52.5%
134,177
+108.2%
0.00%
Q4 2021$1,045,000
+43.3%
64,449
+152.2%
0.00%
Q3 2021$729,000
+1520.0%
25,559
+1790.5%
0.00%
Q2 2021$45,000
+1400.0%
1,352
+1187.6%
0.00%
Q1 2021$3,0000.0%105
+90.9%
0.00%
Q4 2020$3,000
+200.0%
55
+243.8%
0.00%
Q3 2020$1,000
-88.9%
16
-92.7%
0.00%
Q2 2020$9,000
-93.3%
219
-95.7%
0.00%
Q1 2020$134,000
+2133.3%
5,141
+2470.5%
0.00%
Q4 2019$6,000
-98.5%
200
-98.7%
0.00%
Q3 2019$411,000
+661.1%
15,783
+568.8%
0.00%
Q2 2019$54,000
+38.5%
2,360
+60.2%
0.00%
Q1 2019$39,000
-48.0%
1,473
-59.9%
0.00%
Q4 2018$75,0003,6740.00%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Memorial Sloan Kettering Cancer Center 191,176$2,271,0002.63%
Sofinnova Investments, Inc. 2,194,278$26,068,0001.98%
MPM BioImpact LLC 443,702$5,271,0001.42%
Soleus Capital Management, L.P. 238,982$2,839,0000.37%
Lombard Odier Asset Management (Switzerland) SA 221,774$2,635,0000.21%
Artal Group S.A. 400,000$4,752,0000.20%
Polar Capital Holdings Plc 2,877,671$34,187,0000.15%
ASHFORD CAPITAL MANAGEMENT INC 106,770$1,268,0000.14%
Cormorant Asset Management, LP 150,000$1,782,0000.14%
Virtus ETF Advisers LLC 23,646$281,0000.13%
View complete list of Y-MABS THERAPEUTICS INC shareholders